Published in Women's Health Weekly, November 3rd, 1997
Speaking at a September 30, 1997 media workshop in New York City, New York, organized by the National Breast Cancer Coalition (NBCC), Dennis Slamon, M.D., director of the Revlon-UCLA Cancer Research Program, said that preliminary results from a Phase III clinical trial of an antibody treatment designed to block a growth factor produced by the proto-oncogene HER2/neu (also called erb2) look promising.
Dr. Slamon's research has shown that approximately 30 percent of breast tumors (and 20 percent of ovarian tumors) have multiple copies of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.